Inflammatory bowel disease
Inflammatory Bowel Disease (IBD) affects millions of patients around the world, including a million people in the US and 2.5 million people in Europe. Yet efforts to combat these diseases have been frustrated in the past due to the complexity and cost associated with running clinical trials. IBD covers a group of disorders, primarily including ulcerative colitis (UC) and Crohn's Disease (CD), in which all or part of the patient’s digestive tract becomes inflamed. These conditions periodically “flare up” causing the patient severe diarrhea, pain, fatigue and/or weight loss, with the most severe cases leading to life-threatening complications. The lack of new treatments for these diseases has left a significant unmet medical need among IBD patients around the world.
Through many years of successful individual work, we managed to gather opinion leaders, academic institutions and practitioners in gastroenterology, under ClinQuestAdria do drive reach and deliver services to clients from early clinical development to late phase studies.
Clinical support and services
- Advisory services in clinical and protocol development allowing our clients fast decision making and captured opportunities
- Well established relationships and access to experienced investigative sites
- Investigative sites highly experienced in using all international criteria and scoring methods
- Customized qualitative feasibility leading to optimized site selection, reliable performance and preemptive study management
- Development of recruitment strategies tailored to each study and site
- A track record of successful delivery of patient populations, meeting or exceeding recruitment targets within timelines
- In-depth risk assessment and early implementation of mitigation strategies
- Extensive knowledge of local practices and regulations, including standard of care and reimbursement conventions
Other services
